

# A randomised trial investigating therapies needed to maintain remission in dilated cardiomyopathy

|                                        |                                                   |                                                                                                                         |
|----------------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>09/12/2022   | <b>Recruitment status</b><br>No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol                       |
| <b>Registration date</b><br>18/08/2023 | <b>Overall study status</b><br>Ongoing            | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                                  |
| <b>Last Edited</b><br>03/12/2025       | <b>Condition category</b><br>Circulatory System   | <input type="checkbox"/> Individual participant data<br><input checked="" type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

Dilated cardiomyopathy is a common disease of the heart muscle, where it becomes stretched and weak. After treatment with 4 medications, many patients experience resolution of symptoms and improvement in heart function. This is heart failure remission. Patients with heart failure remission often wish to reduce the number of medications they take to alleviate side effects and improve quality of life.

In a previous trial, we showed that 2 out of 5 patients will experience a reduction in heart function if all medications are stopped. Our research suggested that one medication, beta-blockers, may be the most important to maintain remission. It is possible that some others are no longer required. Our research and focus groups conducted with patients and a patient charity have emphasised the importance of further studies investigating the feasibility of reducing the number of medications taken by patients with heart failure remission. This led to the design of this study.

### Who can participate?

We will study 50 patients with remission of dilated cardiomyopathy who are taking 3-4 medications.

### What does the study involve?

Remission will be defined by 1) an improvement in left ventricular ejection fraction (a measure of heart function) to >50%, 2) an N-terminal propeptide of B-type natriuretic peptide (NT-pro-BNP; a blood test measuring heart stress) of <250ng/L and 3) resolution of heart failure symptoms. A computer will randomly select 25 patients to stop 1-2 medications (mineralocorticoid receptor antagonists and sodium glucose co-transporter 2 inhibitors) whilst continuing beta-blockers and medications that inhibit the renin-angiotensin system. The other 25 patients will continue all medications. We will perform heart MRI scans and blood tests and compare heart function between the groups over 4 months. Patients that continued therapy for the first half of the study will have the opportunity to stop the same 1-2 medications in the same fashion between 4-8 months.

What are the possible benefits and risks of participating?

Benefits:

Not provided at time of registration

Risks:

It is possible that patients will experience a deterioration in cardiac function during therapy de-escalation. To mitigate the risk of this, patients will be monitored closely with frequent cardiac imaging, biomarkers and clinical assessment. We previously demonstrated the safety of this strategy in the TRED-HF trial - only one patient developed mild signs of heart failure that resolved with re-introduction of therapy, there were no unplanned heart failure hospitalisations and all those who had a reduction in cardiac function following therapy withdrawal, had a subsequent improvement in function with re-introduction of therapy. We will use a significantly more conservative strategy in this study by only withdrawing a maximum of 2 out of 4 medications for heart failure. We anticipate the risks to be much lower.

Trial participants will be closely monitored by doctors and specialist nurses, experienced in the management of heart failure to identify early markers of deteriorating cardiac function. If there is any suggestion of deterioration, we will ask patients to attend clinic for an earlier review. The results and progress of patients will be reviewed on a regular basis by an adjudication panel led by a Consultant Cardiologist. Strict criteria have been set to identify patients with early adverse effects from reducing their medications. The panel will make prompt decisions to re-establish therapy in patients meeting these criteria. Patients will be educated on the signs and symptoms of heart failure and will be instructed to weigh themselves daily. They will be asked to contact the research team if they develop signs and symptoms of heart failure or their weight increases by 2kg from baseline. A contact telephone number and email will be provided to enable patients to contact the research team with any concerns between 9am-5pm. Out of hours, they will be given the contact number for the Duty Cardiology doctor on call at the Royal Brompton Hospital and they will be asked to contact a member of the research team at the earliest possibility during office hours.

An independent data monitor will review interim trial data and will be informed of all SAEs. They will be able to recommend termination of the study to the Chief Investigator. Our patient information leaflet will inform participants that there is a risk of developing symptoms of heart failure or that their cardiac function will deteriorate as a result of medication withdrawal.

As part of the study, participants will undergo Cardiovascular Magnetic Resonance (CMR). This involves lying in a large magnetic tube for 30-45 minutes. It is not painful, involves no radiation and has no side effects. Participants will hear a noise from the machine. This will be reduced by ear defenders. If participants suffer from claustrophobia, the researchers will discuss the risk that the scan may exacerbate this.

Participants will be given intravenous gadolinium contrast as part of the baseline scan. This is part of routine clinical care and allows the detection of fibrosis which may be an important predictor of response to treatment. Gadolinium is well tolerated by the vast majority of patients. There is small risk of minor allergic reactions. Occasionally this requires treatment with anti-histamines which are available at all scanning locations. Anaphylaxis is very rare. All scanning sessions will be supervised by a doctor trained to deal with this. Anaphylactic medication packs are available at all scanning locations. An allergy history will be taken prior to contrast administration. There is an extremely small risk of nephrogenic systemic fibrosis associated with gadolinium in patients with kidney impairment. For this reason, patients with renal impairment (eGFR <45ml/min) will be excluded from the study.

Current guidelines on the use of CMR in clinical settings recommend that MRI studies be delayed until after pregnancy when possible. SGLT2 inhibitors and MRAs are generally contraindicated in pregnancy. We have therefore included pregnancy or planned pregnancy as an exclusion criteria. Women of child-bearing age will be required to use contraception during the study and have a negative pregnancy test before each CMR scan.

Patients with MR-conditional implantable devices will have scans as per department protocols.

The scanning of MR-conditional devices using such protocols is safe and supported by the Royal College of Radiologists.  
Incidental findings will be communicated to the participants and usual doctors. The latter will be asked to consider further investigation if necessary.

Where is the study run from?  
Imperial College London (UK)

When is the study starting and how long is it expected to run for?  
December 2022 to September 2026

Who is funding the study?  
British Heart Foundation

Who is the main contact?  
Dr Brian Halliday, b.halliday@imperial.ac.uk

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Keith Boland

**Contact details**  
Joint Research and Compliance Office  
Room 221, Medical School Bldg  
St Mary's Campus  
Norfolk Pl  
London  
United Kingdom  
W2 1PG  
-  
rgit.ctimp.team@imperial.ac.uk

**Type(s)**  
Principal investigator

**Contact name**  
Dr Brian Halliday

**Contact details**  
CMR Unit  
Royal Brompton Hospital  
Sydney St  
London  
United Kingdom  
SW3 6NP  
+44 2073528121 ext 2928  
b.halliday@imperial.ac.uk

# Additional identifiers

## ClinicalTrials.gov (NCT)

NCT06091475

## Clinical Trials Information System (CTIS)

2022-003734-39

## Integrated Research Application System (IRAS)

1006543

## Central Portfolio Management System (CPMS)

58108

## Protocol serial number

22HH8010

# Study information

## Scientific Title

A randomised trial examining therapy to maintain remission in dilated cardiomyopathy

## Acronym

TRED-HF2

## Study objectives

Primary objective:

To determine whether it is safe and feasible to stop mineralocorticoid receptor antagonists and sodium glucose co-transporter 2 inhibitors in asymptomatic patients with dilated cardiomyopathy and improved cardiac function who are taking beta-blockers and renin-angiotensin system inhibitors.

Secondary objectives:

1. To determine the relapse rate following withdrawal of mineralocorticoid receptor antagonists and sodium glucose co-transporter 2 inhibitors in asymptomatic patients with dilated cardiomyopathy and improved cardiac function who are taking beta-blockers and renin-angiotensin system inhibitors.
2. To determine if patients with dilated cardiomyopathy and improved cardiac function have specific imaging and genetic phenotypes that predict the occurrence of relapse following the withdrawal of mineralocorticoid receptor antagonists and sodium glucose co-transporter 2 inhibitors.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

Approved 17/08/2023, London Dulwich Research Ethics Committee (Health Research Authority, 2nd Floor, 2 Redman Place, Stratford, London, E20 1JO, United Kingdom; +44 207 104 8286; [dulwich.rec@hra.nhs.uk](mailto:dulwich.rec@hra.nhs.uk)), ref: 23/LO/0052

## Primary study design

Interventional

## Study design

Interventional randomized cross over controlled trial

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Patients with a previous diagnosis of dilated cardiomyopathy who have improved cardiac function and who are asymptomatic

## Interventions

We will do a randomised controlled trial of SGLT2i and MRA withdrawal between the point of randomisation and 16 weeks, with a follow-on phase between 16-32 weeks that will include a single-arm cross-over for those initially randomised to the control arm. Patients will be randomised using an online tool to two arms in a 1:1 ratio using random permuted blocks, stratified by three groups of NT-pro-BNP: 1) <50ng/l, 2) 50-125ng/l, 3) >125ng/L. Patients randomised to Arm B will stop SGLT2i at baseline, followed by MRA at 8 weeks. In the follow-on phase, they will continue follow-up off these medications between 16-32 weeks. Patients randomised to Arm A will continue current therapy between baseline and 16 weeks. After 16 weeks, patients who have continued therapy in Arm A will have the opportunity to enter a single arm cross-over phase and stop MRA followed by SGLT2i at 24 weeks (the reverse order to Arm B in the randomised phase).

## Intervention Type

Drug

## Phase

Phase IV

## Drug/device/biological/vaccine name(s)

Dapagliflozin, empagliflozin, spironolactone, eplerenone

## Primary outcome(s)

Relapse of DCM defined by any one of the following:

1. A reduction in LVEF >10% and to below 50%
2. A two-fold rise in NT-pro-BNP and to >400ng/L or
3. Clinical features of heart failure as determined by the research team.

This is a composite of prognostically important variables supported by the findings of TRED-HF, taking into account changes in markers of cardiac function and congestion. The primary analysis will take place after 16 weeks of the randomised phase. There will also be a follow-on phase. The incidence of the primary end-point will also be assessed between 16-32 weeks.

## Key secondary outcome(s)

At baseline, 16 weeks and 32 weeks:

1. Left ventricular ejection fraction (%) (cardiovascular magnetic resonance [CMR])
2. Left ventricular end-diastolic volume indexed to body surface area (ml/m<sup>2</sup>) (CMR)
3. Left ventricular global longitudinal strain (LV GLS) (CMR)

4. Left ventricular mass index (LVMI; g/m<sup>2</sup>) (CMR)
5. Left atrial volume index (LAVi; ml/m<sup>2</sup>) (CMR)
6. Left atrial strain (LAS) (CMR)
7. Right ventricular ejection fraction (RVEF; %) (CMR)
8. NT-pro-BNP (ng/L) (plasma concentration from peripheral blood sampling)
9. Quality of life: EQ-5D-5L score
10. Treatment Burden Questionnaire score

**Completion date**

01/09/2026

## Eligibility

**Key inclusion criteria**

1. A diagnosis of DCM
2. Previous LVEF <40% (on echocardiography or cardiovascular magnetic resonance [CMR])
3. Current LVEF >50% for at least 6 months duration with normal left ventricular end-diastolic volume (LVEDV) at inclusion
4. Plasma NT-pro-BNP <250ng/L
5. New York Heart Association (NYHA) class I
6. Sinus rhythm
7. Taking a beta-blocker and an ACEi, ARB or sacubitril-valsartan, along with at least one of an MRA or SGLT2i.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

50

**Key exclusion criteria**

1. Current atrial fibrillation
2. Prior sustained ventricular tachycardia or fibrillation
3. A known likely pathogenic or pathogenic variant in LMNA/DSP/FLNC/RBM20
4. Sudden cardiac or heart failure death in a first degree relative <50 years
5. Contraindication to CMR
6. Estimated glomerular filtration rate (eGFR) <45mls/min
7. Current or planned pregnancy
8. Known active myocardial inflammation
9. Another indication for an SGLT2i (diabetes mellitus or CKD)
10. Previous relapse of symptomatic heart failure following initial recovery in function

- 11. Current participation in another CTIMP
- 12. Ongoing need for other heart failure therapies including loop diuretics, ivabradine or digoxin

**Date of first enrolment**

21/10/2023

**Date of final enrolment**

20/11/2025

## **Locations**

**Countries of recruitment**

United Kingdom

**Study participating centre**

**Royal Brompton & Harefield NHS Foundation Trust**

Royal Brompton Hospital

Sydney Street

London

England

SW3 6NP

## **Sponsor information**

**Organisation**

Imperial College London

**ROR**

<https://ror.org/041kmwe10>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

British Heart Foundation

**Alternative Name(s)**

The British Heart Foundation, the\_bhf, BHF

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Trusts, charities, foundations (both public and private)

**Location**

United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Data sharing statement to be made available at a later date